Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB) announced it will report its second quarter 2022 financial results on August 8, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) announced it will report its second quarter 2022 financial results on August 8, 2022, after market close. The company, known for its mission to enhance human health through advanced technologies, is set to host a conference call at 1:30 p.m. PT to discuss its financial outcomes and operational progress. Interested parties can listen via phone or through a live webcast on the company's Investor Relations page.
Positive
- Upcoming financial results announcement on August 8, 2022.
- Management will discuss operational progress during the call.
Negative
- None.
Details
News Market Reaction – LAB
The recorded move for LAB in the trading session of this news was -2.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the market.
The Company’s management will host a conference call and webcast at 1:30 p.m. PT/4:30 p.m. ET, on August 8, 2022, to discuss second quarter 2022 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online from the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTool’s Investor Relations page at investors.standardbiotools.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm, is driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter, Facebook, LinkedIn, and YouTube. Standard BioTools, the Standard BioTools logo, are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbiotools.com), investor site (investors.standardbiotools.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.
Investors:
Peter DeNardo
415 389 6400
ir@standardbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.